KRAS and pancreatic neoplasm: For example, siRNA specific to oncogenic KRAS G12D delivered by engineered exosomes suppress pancreatic cancer in multiple mouse models and significantly increase overall survival.[51] In our study, we developed iRGD‐decorated exosomes loaded with siRNA against BRIX1 and verified that these exosomes could transport siBRIX1 to tumor sites (Figure 7K,L) and increase the uptake of siBRIX1 by cancer cells (Figure 7A,C).